Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-gated potassium channels (VGKCs) in presynaptic motor neurons are critical regulators of neuromuscular transmission, responsible for the repolarization of the nerve terminal membrane following an action potential [1.1.1, 1.3.2]. By mediating the efflux of potassium ions, these channels terminate the electrical signal and limit the duration of calcium influx through voltage-gated calcium channels, which is the primary trigger for neurotransmitter release [1.2.1, 1.5.1]. In pathological conditions such as Lambert-Eaton Myasthenic Syndrome (LEMS), the release of acetylcholine is impaired due to an autoimmune attack on calcium channels [1.2.2, 1.2.4]. Pharmacological targeting of presynaptic VGKCs with blockers like amifampridine (3,4-diaminopyridine) serves to prolong the action potential, thereby increasing the time available for calcium entry and enhancing the exocytosis of acetylcholine [1.2.3, 1.2.5]. This mechanism effectively compensates for the reduced number of functional calcium channels and improves muscle strength in patients with neuromuscular junction disorders [1.2.1, 1.2.2]. Beyond LEMS, these channels are also implicated in other conditions like neuromyotonia and multiple sclerosis, where their modulation can alter neuronal excitability and conduction [1.1.4, 1.3.1].
Blockade of presynaptic voltage-gated potassium channels prolongs the duration of the action potential at the nerve terminal. This extension increases the time that voltage-gated calcium channels remain open, leading to enhanced calcium influx and a subsequent increase in the quantal release of acetylcholine into the synaptic cleft, thereby improving neuromuscular transmission.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated potassium channel (VGKC) (VGKC).